Praeventix

Biotechnology · Health Care
$16.7Mtotal raised · 3 rounds on record
$5.6Mlatest round · Venture round · Feb 2026 · 9 mo ago
50+team · employees, estimated range
2022founded

Overview

About About Praeventix Praeventix is an early-stage biotech company committed to the discovery, research and early clinical development of novel serotonergic therapeutics with potential applications in dermatologic, autoimmune and neurodegenerative diseases.

Funding and backers

Total raised
$16.7M
3 rounds on record
Latest round
$5.6M
Venture round · Feb 2026 · 9 mo ago
Team
51-200
employees, estimated range
The money's age
Fresh money
9 months since the last round · not hiring
Momentum
20/100
fresh money
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Feb 3 Raised a round Venture round $5.6M · SEC Form D May 8, 2025 Raised a round Venture round $6.8M · SEC Form D Oct 26, 2022 Raised a round Venture round $4.3M · SEC Form D 2022 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Feb 2026 $5.6M — SEC Form D
Venture round May 2025 $6.8M — SEC Form D
Venture round Oct 2022 $4.3M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity Praeventix, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Douglas Pippin PhDExecutive Officer, DirectorSEC Form D
Heidi KempinskiExecutive Officer, DirectorSEC Form D
Investors in similar startupsfunds that back the companies most like this one
SOSV
backs Tinkeso Therapeutics
Sofinnova Partners
backs Pincell
Tenoneten
backs PEREGRINE SPACE
Maine Angels
backs Cognition Therapeutics, Inc.
General Inception
backs &&(p
Sofia Fund
backs Cognition Therapeutics, Inc.
Similar startupsby what they do, their industry and backers
Temprian TherapeuticsConvertible Note $275k · 7 yr ago · Founded 2019 · 51-200 employees
Temprian Therapeutics is an early-stage biotechnology company treating vitiligo through a novel treatment that blocks the autoimmune…
&&(p
Early-stage biotech in immunotherapy with an international team of experts and founders aiming to develop and deliver personalized…
Cognition Therapeutics, Inc.
Advancing Accessible Solutions for Complex Neurodegenerative Diseases. Protecting neurons to advance treatment for neurodegenerative…
Pincell
Pincelli is a pre-clinical stage biotech company focused on the development of innovative first-in-class treatments for rare skin diseases.
Tinkeso TherapeuticsFounded 2017 · 1-10 employees
Is to address the patient unmet needs with our novel off-the-shelf, allogeneic Natural Killer T (NKT) cell therapies for the treatment of…
CND Life SciencesSeries A $13.5M · 18 mo ago · Founded 2017
CND advances neurodiagnostics through skin biopsy testing, including the Syn-One Test, for neurodegenerative diseases.

Financials

Total raised
$16.7M
Latest round
Venture - Series Unknown
Funding rounds
3
Funding rounds
Round Announced Amount
Venture - Series Unknown 2026 $5.6M Details
Venture - Series Unknown 2025 $6.8M Details
Venture - Series Unknown 2022 $4.3M Details

People

Douglas Pippin PhD
Executive Officer, Director
SEC Form D
Heidi Kempinski
Executive Officer, Director
SEC Form D
Leon Moulder
Director
SEC Form D
Robert Hankin
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data

Offices

Where the company hires and what each office is for
Cities
1
Hiring now
0
Countries
1
Exton United States
HQ
50-200 est. staff
665 Stockton Drive, Suite 200H, Exton, PA 19341
company site